Araris Biotech Competitors and Similar CompaniesClear all
Araris Biotech's competitors and similar companies include ADC Therapeutics, Mersana Therapeutics, NBE-Therapeutics and Qilu Pharmaceutical.
 Araris Biotech Araris Biotech is a biotechnology company with a new antibody-drug conjugate (ADC)-linker technology. |  ADC Therapeutics ADC Therapeutics is a biotechnology company that develops drug conjugates for the treatment of both solid and haematological cancers. |  Mersana Therapeutics Mersana Therapeutics is a clinical-stage biotechnology company developing antibody-drug conjugate (ADC) platforms. |  NBE-Therapeutics NBE-Therapeutics is a privately owned Swiss, Basel-based Biotech company that was founded in 2012 with the vision to develop next-generation ADCs improving treatment options for cancer patients. |  Qilu Pharmaceutical Qilu Pharmaceutical (齐鲁制药) is a company that develops, manufactures, and markets generic drugs and active pharmaceutical ingredients (APIs). | |
Founding Date | Founding Date 2019 | Founding Date 2010 | Founding Date 2005 | Founding Date 2012 | Founding Date 1958 |
Type | Type Private | Type Public | Type Public | Type Private | Type Private |
Tags | |||||
Locations | Locations Zürich, CH HQ | Locations Epalinges, CH HQ London, GB New Providence, US | Locations Cambridge, US HQ | Locations Basel, CH HQ | Locations Jinan Shi, CN HQ Boston, US |
Employees | Employees 4 | Employees 1162% increase | Employees 11033% increase | Employees N/A | Employees 39,0008% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) 295.9 m | Valuation ($) 250.3 m | Valuation ($) N/A | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $81.4m (FY, 2025) | Revenue (est.) $40.5m (FY, 2024) | Revenue (est.) N/A | Revenue (est.) N/A |
Net income | Net income N/A | Net income ($142.6m) (FY, 2025) | Net income ($69.2m) (FY, 2024) | Net income N/A | Net income N/A |
Funding | |||||
Latest funding round | Latest funding round $ 24m (over 3 years ago) | Latest funding round N/A | Latest funding round N/A | Latest funding round $ 22m (over 6 years ago) | Latest funding round N/A |
Total funding raised | Total funding raised $ 43.4m | Total funding raised $ 526m | Total funding raised $ 219.5m | Total funding raised $ 65.6m | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
ADC Therapeutics
HQ
Epalinges, CH
Employees
116↑ 2% increase
ADC Therapeutics is a biotechnology company that develops drug conjugates for the treatment of both solid and haematological cancers.
View companyMersana Therapeutics
HQ
Cambridge, US
Employees
110↑ 33% increase
Mersana Therapeutics is a clinical-stage biotechnology company developing antibody-drug conjugate (ADC) platforms.
View companyNBE-Therapeutics
HQ
Basel, CH
NBE-Therapeutics is a privately owned Swiss, Basel-based Biotech company that was founded in 2012 with the vision to develop next-generation ADCs improving treatment options for cancer patients.
View companyQilu Pharmaceutical
HQ
Jinan Shi, CN
Employees
39,000↑ 8% increase
Qilu Pharmaceutical (齐鲁制药) is a company that develops, manufactures, and markets generic drugs and active pharmaceutical ingredients (APIs).
View company